Publication: Biomarcadores de respuesta al interferón beta en la esclerosis múltiple
Loading...
Files
Official URL
Full text at PDC
Publication Date
2017-09-01
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La esclerosis múltiple (EM) es una enfermedad crónica del sistema nervioso central (SNC) que se caracteriza por presentar desmielinización, inflamación y daño axonal. El Interferón beta (IFN-beta) fue el primer fármaco inmunomodulador usado en el tratamiento de la esclerosis múltiple remitente-recidivante (EMRR). Es un fármaco seguro y eficaz, capaz de disminuir la actividad de la enfermedad. Sin embargo, la respuesta a este tratamiento no es uniforme en todos los pacientes de EM. Por ello, dado el gran abanico de opciones terapéuticas que existen en la actualidad, la búsqueda de biomarcadores que permitan identificar de manera precoz a los pacientes con alta probabilidad de mostrar una respuesta óptima al interferón beta es de gran relevancia para poder realizar una medicina personalizada en la EM. Hasta ahora son los marcadores clínicos y radiológicos los que más se utilizan para establecer la eficacia de las distintas opciones terapéuticas. Sin embargo, esto implica un cierto deterioro para los pacientes no respondedores que puede repetirse con distintas terapias. Objetivos El primer objetivo del estudio fue identificar antes del inicio del tratamiento, biomarcadores biológicos que predigan la respuesta a IFN-beta. En segundo lugar comparamos los niveles de todos los posibles marcadores incluidos en el estudio con los de los controles sanos. Nuestro último objetivo fue analizar los cambios que el tratamiento podría inducir en todos los factores estudiados...
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by presenting with demyelination, axonal damage and inflammation. Interferon beta (IFN-beta) was the first immunomodulatory drug used in the treatment of relapsing-remitting multiple sclerosis (RRMS). It is a safe and effective treatment able to diminish the activity of the disease. However, the response to this treatment is not uniform in all MS patients. Therefore, given the wide range of therapeutic options existing actually in MS, the search for biomarkers that allow the early identification of patients with high probability of showing an optimal response to beta interferon is of great importance to perform a personalized medicine in MS. Actually, the most used markers to establish treatment efficacy are clinical and radiological data. However, this implies certain deterioration for non-responder patients, which may occur with different therapies. Objective The first objective of the study was to identify, before treatment initiation, biomarkers that predict patient response to IFN-beta. Secondly we compared the levels of the different molecules and cell subsets included in the study with healthy controls. Our ultimate goal was to analyse the changes induced by treatment in all the factors studied...
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by presenting with demyelination, axonal damage and inflammation. Interferon beta (IFN-beta) was the first immunomodulatory drug used in the treatment of relapsing-remitting multiple sclerosis (RRMS). It is a safe and effective treatment able to diminish the activity of the disease. However, the response to this treatment is not uniform in all MS patients. Therefore, given the wide range of therapeutic options existing actually in MS, the search for biomarkers that allow the early identification of patients with high probability of showing an optimal response to beta interferon is of great importance to perform a personalized medicine in MS. Actually, the most used markers to establish treatment efficacy are clinical and radiological data. However, this implies certain deterioration for non-responder patients, which may occur with different therapies. Objective The first objective of the study was to identify, before treatment initiation, biomarkers that predict patient response to IFN-beta. Secondly we compared the levels of the different molecules and cell subsets included in the study with healthy controls. Our ultimate goal was to analyse the changes induced by treatment in all the factors studied...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, Departamento de Microbiología I, leída el 01-02-2016